Covalent ISG15 conjugation positively regulates the ubiquitin E3 ligase activity of parkin

Open Biology

Volumn 6, Issue 8, 2016, Pages

  Im, Eunju ^a,b,c   Yoo, Lang ^a   Hyun, Minju ^a   Shin, Woo Hyun ^a   Chung, Kwang Chul ^a  

^a Yonsei University   (South Korea)

^b NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

E3 ligase; HERC5; ISG15; ISGylation; Parkin; Parkinson's disease

Indexed keywords

CYTOKINE; HERC5 PROTEIN, HUMAN; ISG15 PROTEIN, HUMAN; LYSINE; PARKIN; SIGNAL PEPTIDE; UBIQUITIN; UBIQUITIN PROTEIN LIGASE;

ANIMAL; BINDING SITE; CELL LINE; CHEMISTRY; CHLOROCEBUS AETHIOPS; CV-1 CELL LINE; GENETICS; HEK293 CELL LINE; HELA CELL LINE; HUMAN; METABOLISM; MISSENSE MUTATION; MOUSE; NIH 3T3 CELL LINE; PARKINSON DISEASE;

ANIMALS; BINDING SITES; CELL LINE; CERCOPITHECUS AETHIOPS; COS CELLS; CYTOKINES; HEK293 CELLS; HELA CELLS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LYSINE; MICE; MUTATION, MISSENSE; NIH 3T3 CELLS; PARKINSON DISEASE; UBIQUITIN-PROTEIN LIGASES; UBIQUITINS;

EID: 84990933993     PISSN: None     EISSN: 20462441     Source Type: Journal    
DOI: 10.1098/rsob.160193     Document Type: Article

References (63)

1. de Rijk MC, Tzourio C, Breteler MM, Dartigues JF, Amaducci L, Lopez-Pousa S, Manubens-Bertran JM, Alpérovitch A, Rocca WA. 1997 Prevalence of Parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European community concerted action on the epidemiology of Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 62, 10-15. (doi:10.1136/jnnp.62.1.10)
2. Chai C, Lim KL. 2013 Genetic insights into sporadic Parkinson's disease pathogenesis. Curr. Genomics 14, 486-501. (doi:10.2174/1389202914666 131210195808)
3. Joch M, Ase AR, Chen CX, MacDonald PA, Kontogiannea M, Corera AT, Brice A, Séguéla P, Fon EA. 2007 Parkin-mediated monoubiquitination of the PDZ protein PICK1 regulates the activity of acid-sensing ion channels. Mol. Biol. Cell. 18, 3105-3118. (doi:10.1091/mbc.E05-11-1027)
4. Hampe C, Ardila-Osorio H, Fournier M, Brice A, Corti O. 2006 Biochemical analysis of Parkinson's disease-causing variants of Parkin, an E3 ubiquitinprotein ligase with monoubiquitylation capacity. Hum. Mol. Genet. 15, 2059-2075. (doi:10.1093/hmg/ddl131)
5. 2+-binding domain in the autosomal recessive juvenile Parkinson-related E3 ligase parkin. J. Biol. Chem. 284, 14 978-14 986. (doi:10.1074/jbc.M808700200)
6. Dawson TM, Dawson VL. 2003 Rare genetic mutations shed light on the pathogenesis of Parkinson disease. J. Clin. Invest. 111, 145-151. (doi:10.1172/JCI200317575)
7. Sandebring A, Cedazo-Minguez A. 2012 Parkin-an E3 ubiquitin ligase with multiple substrates. J. Alzheimers Dis. Parkinsonism S10, 002.
8. Scarffe LA, Stevens DA, Dawson VL, Dawson TM. 2014 Parkin and PINK1: much more than mitophagy. Trends Neurosci. 37, 315-324. (doi:10.1016/j.tins.2014.03.004)
9. Pickrell AM, Youle RJ. 2015 The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease. Neuron 85, 257-273. (doi:10.1016/j. neuron.2014.12.007)
10. Durcan TM, Fon EA. 2015 The three 'P's of mitophagy: PARKIN, PINK1, and post-translational modifications. Genes Dev. 29, 989-999. (doi:10.1101/gad.262758.115)
11. Rubio de la Torre E, Gómez-Suaga P, Martínez-Salvador M, Hilfiker S. 2011 Posttranslational modifications as versatile regulators of parkin function. Curr. Med. Chem. 18, 2477-2485. (doi:10.2174/092986711795843254)
12. Um JW, Chung KC. 2006 Functional modulation of parkin through physical interaction with SUMO-1. J. Neurosci. Res. 84, 1543-1554. (doi:10.1002/jnr.21041)
13. Um JW, Han KA, Im E, Oh Y, Lee K, Chung KC. 2012 Neddylation positively regulates the ubiquitin E3 ligase activity of parkin. J. Neurosci. Res. 90, 1030-1042. (doi:10.1002/jnr.22828)
14. Haas AL, Ahrens P, Bright PM, Ankel H. 1987 Interferon induces a 15-kilodalton protein exhibiting marked homology to ubiquitin. J. Biol. Chem. 262, 11 315-11 323.
15. Narasimhan J, Wang M, Fu Z, Klein JM, Haas AL, Kim JJ. 2005 Crystal structure of the interferoninduced ubiquitin-like protein ISG15. J. Biol. Chem. 280, 27 356-27 365. (doi:10.1074/jbc. M502814200)
16. Loeb KR, Haas AL. 1992 The interferon-inducible 15-kDa ubiquitin homolog conjugates to intracellular proteins. J. Biol. Chem. 267, 7806-7813.
17. Yuan W, Krug RM. 2001 Influenza B virus NS1 protein inhibits conjugation of the interferon (IFN)-induced ubiquitin-like ISG15 protein. EMBO J. 20, 362-371. (doi:10.1093/emboj/20.3.362)
18. Zhao C, Beaudenon SL, Kelley ML, Waddell MB, Yuan W, Schulman BA, Huibregtse JM, Krug RM. 2004 The UbcH8 ubiquitin E2 enzyme is also the E2 enzyme for ISG15, an IFN-alpha/beta-induced ubiquitin-like protein. Proc. Natl Acad. Sci. USA 101, 7578-7582. (doi:10.1073/pnas.0402528101)
19. Zhang D, Zhang DE. 2011 Interferon-stimulated gene 15 and the protein ISGylation system. J. Interferon Cytok. Res. 31, 119-130. (doi:10.1089/jir.2010.0110)
20. Malakhov MP, Malakhova OA, Kim KI, Ritchie KJ, Zhang DE. 2002 UBP43 (USP18) specifically removes ISG15 from conjugated proteins. J. Biol. Chem. 277, 9976-9981. (doi:10.1074/jbc.M109078200)
21. Jeon YJ et al. 2009 ISG15 modification of filamin B negatively regulates the type I interferon-induced JNK signalling pathway. EMBO Rep. 10, 374-380. (doi:10.1038/embor.2009.23)
22. Zou W, Papov V, Malakhova O, Kim KI, Dao C, Li J, Zhang DE. 2005 ISG15 modification of ubiquitin E2 Ubc13 disrupts its ability to form thioester bond with ubiquitin. Biochem. Biophys. Res. Commun. 336, 61-68. (doi:10.1016/j.bbrc.2005.08.038)
23. Shi HX, Yang K, Liu X, Liu XY, Wei B, Shan YF, Zhu LH, Wang C. 2010 Positive regulation of interferon regulatory factor 3 activation by Herc5 via ISG15 modification. Mol. Cell Biol. 30, 2424-2436. (doi:10.1128/MCB.01466-09)
24. D'Cunha J, Ramanuiam S, Wagner RJ, Witt PL, Knight Jr E, Borden EC. 1996 In vitro and in vivo secretion of human ISG15, an IFN-induced immunomodulatory cytokine. J. Immunol. 157, 4100-4108.
25. D'Cunha J, Knight Jr E, Haas AL, Truitt RL, Border EC. 1996 Immunoregulatory properties of ISG15, an interferon-induced cytokine. Proc. Natl Acad. Sci. USA 93, 211-215. (doi:10.1073/pnas.93.1.211)
26. Desai SD, Haas AL, Wood LM, Tsai YC, Pestka S, Rubin EH, Saleem A, Nur-E-Kamal A, Liu LF. 2006 Elevated expression of ISG15 in tumor cells interferes with the ubiquitin/26S proteasome pathway. Cancer Res. 66, 921-928. (doi:10.1158/0008-5472.CAN-05-1123)
27. Malakhov MP, Kim KI, Malakhova OA, Jacobs BS, Borden EC, Zhang DE. 2003 High-throughput immunoblotting. Ubiquitin-like protein ISG15 modifies key regulators of signal transduction. J. Biol. Chem. 278, 16 608-16 613. (doi:10.1074/jbc.M208435200)
28. Takeuchi T, Inoue S, Yokosawa H. 2006 Identification and Herc5-mediated ISGylation of novel target proteins. Biochem. Biophys. Res. Commun. 348, 473-477. (doi:10.1016/j.bbrc.2006.07.076)
29. Stichel CC, Augustin M, Kühn K, Zhu XR, Engels P, Ullmer C, Lübbert H. 2000 Parkin expression in the adult mouse brain. Eur. J. Neurosci. 12, 4181-4194.
30. Min B, Kwon YC, Choe KM, Chung KC. 2015 PINK1 phosphorylates transglutaminase 2 and blocks its proteasomal degradation. J. Neurosci. Res. 93, 722-735. (doi:10.1002/jnr.23535)
31. Durfee LA, Lyon N, Seo K, Huibregtse JM. 2010 The ISG15 conjugation system broadly targets newly synthesized proteins: implications for the antiviral function of ISG15. Mol. Cell. 38, 722-732. (doi:10.1016/j.molcel.2010.05.002)
32. Shimura H et al. 1999 Immunohistochemical and subcellular localization of Parkin protein: absence of protein in autosomal recessive juvenile parkinsonism patients. Ann. Neurol. 45, 668-672. (doi:10.1002/1531-8249(199905)45:5<668::AIDANA19>3.0. CO;2-Z)
33. Kim Y, Park J, Kim S, Song S, Kwon SK, Lee SH, Kitada T, Kim JM, Chung J. 2008 PINK1 controls mitochondrial localization of Parkin through direct phosphorylation. Biochem. Biophys. Res. Commun. 377, 975-980. (doi:10.1016/j.bbrc.2008.10.104)
34. Matsuda N, Kitami T, Suzuki T, Mizuno Y, Hattori N, Tanaka K. 2006 Diverse effects of pathogenic mutations of Parkin that catalyze multiple monoubiquitylation in vitro. J. Biol. Chem. 281, 3204-3209. (doi:10.1074/jbc.M510393200)
35. Kazlauskaite A et al. 2015 Binding to serine 65-phosphorylated ubiquitin primes Parkin for optimal PINK1-dependent phosphorylation and activation. EMBO Rep. 16, 939-954. (doi:10.15252/embr. 201540352)
36. Kumar A et al. 2015 Disruption of the autoinhibited state primes the E3 ligase parkin for activation and catalysis. EMBO J. 34, 2506-2521. (doi:10.15252/embj.201592337)
37. Wauer T, Simicek M, Schubert A, Komander D. 2015 Mechanism of phospho-ubiquitin-induced PARKIN activation. Nature 524, 370-374. (doi:10.1038/nature14879)
38. Chaugule VK, Burchell L, Barber KR, Sidhu A, Leslie SJ, Shaw GS, Walden H. 2011 Autoregulation of Parkin activity through its ubiquitin-like domain. EMBO J. 30, 2853-2867. (doi:10.1038/emboj.2011.204)
39. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. 1998 How cells respond to interferons. Annu. Rev. Biochem. 67, 227-264. (doi:10.1146/annurev.biochem.67.1.227)
40. Müller M et al. 1993 The protein tyrosine kinase JAK1 complements defects in interferon-alpha/beta and -gamma signal transduction. Nature 366, 129-135. (doi:10.1038/366129a0)
41. van Boxel-Dezaire AH, Rani MR, Stark GR. 2006 Complex modulation of cell type-specific signaling in response to type I interferons. Immunity 25, 361-372. (doi:10.1016/j.immuni. 2006.08.014)
42. Nicholl MJ, Robinson LH, Preston CM. 2000 Activation of cellular interferon-responsive genes after infection of human cells with herpes simplex virus type 1. J. Gen. Virol. 81, 2215-2218. (doi:10.1099/0022-1317-81-9-2215)
43. Kim KI, Malakhova OA, Hoebe K, Yan M, Beutler B, Zhang DE. 2005 Enhanced antibacterial potential in UBP43-deficient mice against Salmonella typhimurium infection by up-regulating type I IFN signaling. J. Immunol. 175, 847-857. (doi:10.4049/jimmunol.175.2.847)
44. Liu M, Hummer BT, Li X, Hassel BA. 2004 Camptothecin induces the ubiquitin-like protein, ISG15, and enhances ISG15 conjugation in response to interferon. J. Interferon Cytok. Res. 24, 647-654. (doi:10.1089/jir.2004.24.647)
45. Dao CT, Luo JK, Zhang DE. 2006 Retinoic acidinduced protein ISGylation is dependent on interferon signal transduction. Blood Cells Mol. Dis. 36, 406-413. (doi:10.1016/j.bcmd. 2006.02.005)
46. Denison SR, Wang F, Becker NA, Schule B, Kock N, Phillips LA, Klein C, Smith DI. 2003 Alterations in the common fragile site gene Parkin in ovarian and other cancers. Oncogene 22, 8370-8378. (doi:10.1038/sj.onc.1207072)
47. Jiang H, Ren Y, Zhao J, Feng J. 2004 Parkin protects human dopaminergic neuroblastoma cells against dopamine-induced apoptosis. Hum. Mol. Genet. 13, 1745-1754. (doi:10.1093/hmg/ddh180)
48. Riedel M, Goldbaum O, Wille M, Richter-Landsberg C. 2011 Membrane lipid modification by docosahexaenoic acid (DHA) promotes the formation of α-synuclein inclusion bodies immunopositive for SUMO-1 in oligodendroglial cells after oxidative stress. J. Mol. Neurosci. 43, 290-302. (doi:10.1007/s12031-010-9439-5)
49. Weetman J, Wong MB, Sharry S, Rcom-H'cheo-Gauthier A, Gai WP, Meedeniya A, Pountney DL. 2013 Increased SUMO-1 expression in the unilateral rotenone-lesioned mouse model of Parkinson's disease. Neurosci. Lett. 544, 119-124. (doi:10.1016/j.neulet.2013.03.057)
50. Mori F, Nishie M, Piao YS, Kito K, Kamitani T, Takahashi H, Wakabayashi K. 2005 Accumulation of NEDD8 in neuronal and glial inclusions of neurodegenerative disorders. Neuropathol. Appl. Neurobiol. 31, 53-61. (doi:10.1111/j.1365-2990. 2004.00603.x)
51. Dil Kuazi A, Kito K, Abe Y, Shin RW, Kamitani T, Ueda N. 2003 NEDD8 protein is involved in ubiquitinated inclusion bodies. J. Pathol. 199, 259-266. (doi:10.1002/path.1283)
52. Shinbo Y, Niki T, Taira T, Ooe H, Takahashi-Niki K, Maita C, Seino C, Iguchi-Ariga SM, Ariga H. 2006 Proper SUMO-1 conjugation is essential to DJ-1 to exert its full activities. Cell Death Differ. 13, 96-108. (doi:10.1038/sj.cdd. 4401704)
53. Kim YM, Jang WH, Quezado MM, Oh Y, Chung KC, Junn E, Mouradian MM. 2011 Proteasome inhibition induces α-synuclein SUMOylation and aggregate formation. J. Neurol. Sci. 307, 157-161. (doi:10.1016/j.jns.2011.04.015)
54. Oh Y, Kim YM, Mouradian MM, Chung KC. 2011 Human Polycomb protein 2 promotes α-synuclein aggregate formation through covalent SUMOylation. Brain Res. 1381, 78-89. (doi:10.1016/j.brainres. 2011.01.039)
55. Choo YS, Vogler G, Wang D, Kalvakuri S, Iliuk A, Tao WA, Bodmer R, Zhang Z. 2012 Regulation of parkin and PINK1 by neddylation. Hum. Mol. Genet. 21, 2514-2523. (doi:10.1093/hmg/dds070)
56. de Weerd NA, Samarajiwa SA, Hertzog PJ. 2007 Type I interferon receptors: biochemistry and biological functions. J. Biol. Chem. 282, 20 053-20 057. (doi:10.1074/jbc.R700006200)
57. Frank-Cannon TC et al. 2008 Parkin deficiency increases vulnerability to inflammation-related nigral degeneration. J. Neurosci. 28, 10 825-10 834. (doi:10.1523/JNEUROSCI.3001-08.2008)
58. Tran TA, Nguyen AD, Chang J, Goldberg MS, Lee JK, Tansey MG. 2011 Lipopolysaccharide and tumor necrosis factor regulate Parkin expression via nuclear factor-kappa B. PLoS ONE 6, e23660. (doi:10.1371/journal.pone.0023660)
59. Ledesma MD, Galvan C, Hellias B, Dotti C, Jensen PH. 2002 Astrocytic but not neuronal increased expression and redistribution of parkin during unfolded protein stress. J. Neurochem. 83, 1431-1440. (doi:10.1046/j.1471-4159.2002. 01253.x)
60. Henn IH et al. 2007 Parkin mediates neuroprotection through activation of IκB kinase/nuclear factor-κB signaling. J. Neurosci. 27, 1868-1878. (doi:10.1523/JNEUROSCI.5537-06. 2007)
61. Riley BE et al. 2013 Structure and function of Parkin E3 ubiquitin ligase reveals aspects of RING and HECT ligases. Nat. Commun. 4, 1982. (doi:10.1038/ncomms2982)
62. Wauer T, Komander D. 2013 Structure of the human Parkin ligase domain in an autoinhibited state. EMBO J. 32, 2099-2112. (doi:10.1038/emboj. 2013.125)
63. Trempe JF et al. 2013 Structure of parkin reveals mechanisms for ubiquitin ligase activation. Science 340, 1451-1455. (doi:10.1126/science. 1237908)